Skip to content

CanWalk: a walking intervention for people with recurrent or metastatic cancer

A study to assess the acceptability and feasibility of a walking intervention for people with recurrent or metastatic cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN42072606
Enrollment
60
Registered
2014-04-16
Start date
2014-04-01
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or metastatic cancer Cancer

Interventions

The intervention comprises a brief (10-minute) telephone or face-to-face session, based on NICE public health guidance on physical activity (NICE, 2013). It will discuss the importance and benefits of

Sponsors

King's College London (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 16 years of age or older 2. Diagnosed with metastatic or recurrent cancer in the previous 6 months 3. Able to walk for a minimum of 30 minutes unaided

Exclusion criteria

Exclusion criteria: 1. Bone metastases that the clinician in charge of the patient's care considers a contra-indication to participating in the walking intervention 2. Unable to speak and understand English

Design outcomes

Primary

MeasureTime frame
The feasibility and acceptability of a walking intervention that combines a motivational element with a pre-existing and nationally available walking programme

Secondary

MeasureTime frame
Participants will complete the following questionnaires at baseline (T0), 6 (T1), 12 (T2) and 24 (T3) weeks: 1. Quality of Life (Functional Assessment of Cancer Therapy scale- General; EuroQol) 2. Physical activity level (Scottish Physical Activity Questionnaire; General Practice Physical Activity Questionnaire) 3. Fatigue (Brief Fatigue Inventory) 4. Distress (depression anxiety stress scales) 5. Exercise self-efficacy (Spinal Cord Injury, to measure exercise self-efficacy) At baseline and 24 weeks participants? performance status will also be assessed (Eastern Cooperative Oncology Group) and the strength of their motivation to change behaviour using a brief ?ruler? (100 mm visual analogue scale)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 18, 2026